The Association is a point of reference for people with achondroplasia and their families .
Copyright 2017 @ acondroplasiaonlus.it
All right reserved
Via Valmasino, 8 - 04011
Therachon announced, on February 14, 2018, the beginning of the Phase 1 clinical study of TA-46 for achondroplasia. The study will take place in the Netherlands, with 70 healthy adult volunteers and will: a randomized, placebo-controlled, double-blind. The study designed with the purpose to evaluate the safety, tolerability and pharmacokinetics of the product.
Vosoritide (BMN 111 for Achondroplasia.
Vosoritide is designed for the treatment of achondroplasia, the most common form of dwarfism.
Discovered a mechanism responsible for the growth of the bones
Researchers at the Telethon Institute of Pozzuoli have discovered a new biological process that allows the bones to grow properly. The work opens up perspectives for the testing of medicines for diseases of the skeleton.